How General Catalyst's Health Bets Outperformed Everyone Else

The Numbers That Made Everyone Pay Attention

In October 2024, General Catalyst announced an $8 billion fundraise-their largest ever. Within that, they committed $750 million to healthcare tech and delivery. What made investors sit up was the timing: healthcare venture had been bleeding dry for two years. While AI got 31% of all venture capital in 2024, healthcare startups were fighting for scraps. Yet General Catalyst doubled down.

That bet has paid off spectacularly. Their health portfolio has generated some of the best returns in their entire fund, with exits like Ro, Ginger, and Vida Health delivering multiples that rival their software plays. This isn't luck. It's thesis-driven investing executed with surgical precision.

For founders raising capital-especially in healthcare-understanding how General Catalyst thinks about health tech reveals something crucial: the best returns don't come from chasing hype. They come from solving real problems with unfair advantages. This deep dive breaks down their playbook, the specific bets that worked, and how you can apply their framework to your own fundraising strategy.

Why Healthcare Was Undervalued (And Why General Catalyst Saw It First)

In 2022 and 2023, healthcare venture was in a reckoning. Digital health had been overfunded during the pandemic. Companies like Teladoc, Livongo, and Ro had gone public and then crashed. LPs were gun-shy. The narrative became: "Healthcare is broken, but it's too hard to fix."

Most VCs retreated. They chased AI, fintech, and climate tech instead. But General Catalyst's thesis was contrarian: healthcare wasn't broken because the market was small-it was broken because it was massive and fragmented. A $4.5 trillion U.S. healthcare system with no dominant players in most segments meant the winner-take-most dynamics that created billion-dollar software companies could work in health too.

The key difference? You had to understand the buyer. Healthcare isn't B2C software. It's B2B2C, or B2B, or B2G (government). You need distribution channels, regulatory know-how, and unit economics that work at scale. General Catalyst had built this expertise over a decade. When everyone else was selling, they were buying.

Their Health Assurance Fund II, launched in 2022 with $670 million, was the first signal. The fund explicitly targeted health system partnerships and digital transformation-not direct-to-consumer plays. This was a deliberate pivot away from the Ro and Teladoc model and toward infrastructure and B2B2C.

The Portfolio: Where the Real Returns Came From

General Catalyst's health wins fall into three buckets: care delivery optimization, AI-enabled diagnostics and operations, and marketplace infrastructure.

Care Delivery Optimization

Ro is the flagship. They started as a telehealth platform for prescriptions, but General Catalyst helped them pivot toward chronic disease management-particularly GLP-1 prescribing for weight loss and diabetes. The market for GLP-1 is estimated at $100+ billion globally by 2030. Ro didn't invent the drug, but they built the distribution and retention engine.

What made General Catalyst's thesis work here: they invested early (Series A), understood that the real margin wasn't in the telehealth consult-it was in the subscription and ongoing care. They helped Ro build a unit economics model where customer acquisition cost was $150-200 but lifetime value was $2,000+. That's venture-scale math.

Ginger (mental health platform) followed a similar playbook. Instead of competing on price with BetterHelp, Ginger focused on employer partnerships and integration with existing benefits. General Catalyst recognized that employers were desperate for mental health solutions that actually moved the needle on employee outcomes. The distribution was built-in.

AI-Enabled Operations and Diagnostics

This is where General Catalyst's healthcare bets intersect with the AI wave. They backed companies like Tempus, which uses AI to analyze oncology data and match patients to trials and treatments. The business model is B2B2C: hospitals and oncologists use the platform, which improves outcomes and generates data.

The return math: Tempus raised at a $8.1 billion valuation in 2023. General Catalyst was an early investor. The company is solving a real problem (treatment matching in cancer), has a defensible moat (proprietary data + AI), and operates in a market (oncology) where customers will pay premium prices for outcomes improvement.

Another example: General Catalyst's healthcare fund backed companies building AI for clinical documentation, prior authorization automation, and hospital operations. These aren't sexy, but they're profitable. A hospital system can save $2-5 million per year by automating prior auth. That's a $50K+ ACV business with 80%+ gross margins.

Marketplace Infrastructure

General Catalyst also invested in platforms connecting supply and demand in fragmented healthcare markets. Companies like Ro (again) and others in mental health, physical therapy, and home care all follow the same pattern: fragmented supply, fragmented demand, broken information flow, and regulatory complexity that creates moats.

The thesis: whoever builds the most reliable, compliant, and easy-to-use marketplace in a healthcare segment wins. It's similar to how Uber dominated ride-sharing, but in healthcare, network effects are stronger because of switching costs and regulatory lock-in.

The Operating Model: How General Catalyst Actually Works with Portfolio Companies

General Catalyst's returns aren't just about picking winners. They're about building winners through hands-on operating support. This is where their healthcare strategy differs from most VCs.

Deep Industry Expertise

General Catalyst employs former hospital executives, healthcare entrepreneurs, and regulatory experts. They don't just write checks; they embed themselves in portfolio companies. When a founder is designing their go-to-market strategy, they have access to someone who has actually sold software to hospital systems.

This matters because healthcare has a long sales cycle (6-18 months) and complex buying committees. A founder who doesn't understand hospital procurement will raise money, burn cash, and fail. General Catalyst's operating team shortens this learning curve by 12-24 months.

Regulatory and Compliance Support

Healthcare is regulated. FDA, CMS, state medical boards, HIPAA-the compliance burden is real. Most VCs are terrified of it. General Catalyst treats it as a moat. They have relationships with regulatory consultants and in-house expertise to help founders navigate FDA clearances, Medicare coding, and state licensing.

When a founder is raising Series A, having already achieved FDA clearance or Medicare coverage is a massive signal to investors. General Catalyst helps portfolio companies hit these milestones earlier, which accelerates fundraising and valuation growth.

Distribution and Partnership Facilitation

General Catalyst's most underrated superpower is their ability to introduce portfolio companies to health systems, hospital networks, and payers. They have relationships with the C-suite at major health systems. When a General Catalyst company needs to pilot their product at a 500-bed hospital network, General Catalyst often opens the door.

This is worth tens of millions of dollars in future revenue. A successful pilot becomes a case study, which becomes a reference customer, which becomes a major contract. Most startups spend 18 months trying to get that first pilot. General Catalyst portfolio companies get it in 6 months.

The Valuation and Return Math: Why Healthcare Bets Outperformed

Let's work through a concrete example using real General Catalyst bets.

Scenario: A Series A investment in a hospital operations AI company

• Entry valuation: $50 million (post-money)
• Check size: $10 million (20% stake)
• Series B (18 months later): $200 million valuation, $40 million raise
• Series C (3 years later): $800 million valuation, $150 million raise
• Exit (5-7 years): Acquired by a major healthcare IT company (Epic, Cerner, etc.) for $2.4 billion

General Catalyst's 20% stake at Series A is worth $480 million at exit. Return: 48x.

This isn't theoretical. Companies like Livongo (acquired by Teladoc for $18.5 billion, with General Catalyst as an early investor) and Ro (valued at $5+ billion) have generated these kinds of returns.

Why did healthcare outperform? Several reasons:

1. Less crowded market. AI got 31% of venture capital in 2024. Healthcare got maybe 8-10%. This means less competition for deal flow, lower valuations at entry, and more room for upside.

2. Larger TAMs. A healthcare SaaS company targeting hospital operations can address a $100+ billion market. A B2B SaaS company in most verticals tops out at $10-20 billion. Larger TAM = larger exit values.

3. Stickier customers. Once a hospital deploys a system, switching costs are astronomical. Customers don't leave. This means predictable revenue, lower churn, and higher valuations at exit.

4. Regulatory moats. FDA clearances, CMS coding, and state licensing create defensible positions. A competitor can't just copy your product; they have to go through a 2-3 year regulatory process.

5. Better unit economics. Healthcare software has higher ACV (average contract value), lower CAC (customer acquisition cost), and higher gross margins than consumer software. This means profitability is achievable earlier, which attracts strategic acquirers.

The AI Intersection: Where Healthcare and AI Collide

General Catalyst's newest healthcare bets are explicitly at the intersection of AI and healthcare. This is where the next wave of returns will come from.

The thesis: healthcare generates more data than any other industry, but that data is fragmented, unstructured, and underutilized. AI can unlock value by:

• Automating clinical documentation: Doctors spend 30-40% of their time on paperwork. AI can transcribe patient conversations and auto-populate EHR records. Savings: $100K+ per physician per year.
• Improving diagnostics: AI can analyze medical imaging, pathology slides, and genetic data faster and sometimes more accurately than humans. This improves outcomes and reduces malpractice risk.
• Optimizing operations: Hospitals can use AI to predict patient no-shows, optimize staffing, and reduce readmissions. Each of these represents $1-10 million in annual savings for a large health system.
• Enabling precision medicine: AI can match patients to treatments based on their genetic profile and medical history. This is the future of oncology and rare disease treatment.

General Catalyst's $8 billion fundraise explicitly calls out AI as a priority. They're backing companies at all three levels: AI for clinicians, AI for operations, and AI for patients.

The key insight: AI in healthcare is not about replacing doctors. It's about amplifying them. The best AI healthcare companies enhance clinical decision-making, reduce administrative burden, and improve outcomes. That's a value proposition that resonates with hospital C-suites and payers.

What Founders Should Learn: The General Catalyst Healthcare Playbook

If you're a healthcare founder raising capital, here's what General Catalyst's success teaches you:

1. Pick a Problem Worth Solving

Don't build a me-too telehealth app. Pick a specific, high-impact problem: prior authorization delays, clinical documentation burden, hospital readmissions, oncology treatment matching, etc. The bigger the problem and the more money it costs the healthcare system, the more willing they are to pay.

General Catalyst's playbook is to find problems where solving them creates $10+ million in annual value for the customer. At that level, a $50K-500K annual software subscription is a no-brainer.

2. Understand Your Buyer

Who actually makes the buying decision? Is it a hospital CFO (looking to save money), a Chief Medical Officer (looking to improve outcomes), a Chief Information Officer (looking to reduce IT burden), or a payer (looking to reduce claims)? Each buyer has different incentives and different approval processes.

General Catalyst spends months understanding the buyer before they even pitch. They ask: How long is the sales cycle? Who are the stakeholders? What's the approval process? What's the budget? If you can't answer these questions clearly, you're not ready to raise.

3. Build Unit Economics That Work

Healthcare SaaS companies need to hit specific metrics to be venture-scale:

• CAC (Customer Acquisition Cost): $50K-200K per customer
• ACV (Annual Contract Value): $100K-500K+ per customer
• Gross Margin: 70%+ (you need this to fund sales and marketing)
• Payback Period: 18-36 months (the time it takes to recover CAC from gross profit)
• Churn: <10% annual (healthcare customers should be sticky)

If your unit economics don't hit these benchmarks, you won't raise Series A from tier-one investors. General Catalyst won't even look at you.

4. Get Early Validation

The best healthcare founders don't just pitch an idea. They have a pilot with a real hospital or health system. They have data showing that their product improves outcomes, reduces costs, or both.

General Catalyst's portfolio companies typically raise Series A with 1-3 paying customers and $100K-500K in ARR (annual recurring revenue). That's not a lot, but it proves the model works. Without that validation, you're just pitching theory.

5. Hire Healthcare Domain Experts

You don't need to be a doctor, but you need people on your team who understand healthcare. This could be a former hospital executive, a clinical operations leader, or someone with deep payer experience. They're worth their weight in gold because they can navigate the complexity that kills most healthtech startups.

General Catalyst looks for founding teams with at least one person who has "done this before" in healthcare. That person is your translator between the startup world and the healthcare world.

The Competitive Landscape: Why General Catalyst Won

General Catalyst wasn't the only VC backing healthcare companies. Sequoia, Andreessen Horowitz, and Khosla Ventures all have healthcare practices. So why did General Catalyst's bets outperform?

Timing and contrarianism. While other VCs were chasing AI and climate tech, General Catalyst was buying healthcare assets cheap. They got better terms and lower valuations.

Operational support. General Catalyst's healthcare team is deeper and more hands-on than most other VCs. This translates to faster company building and better outcomes.

Patient capital. General Catalyst has longer hold periods than most VCs. They're willing to wait 7-10 years for an exit instead of 5-7. This gives portfolio companies time to build real defensible businesses.

Distribution relationships. General Catalyst's relationships with health systems, payers, and healthcare IT companies are unmatched. This is worth tens of millions of dollars in portfolio company value.

For context, check out how other thesis-driven VCs approach their markets. 2048 Ventures backs visionary founders at the earliest stage using a similar playbook: deep expertise, hands-on support, and a long-term view.

Lessons for Healthcare Founders Raising Capital

If you're a healthcare founder, here's how to position yourself for success with General Catalyst or similar investors:

Know Your Numbers

Before you pitch, you should be able to articulate:

• Total addressable market (TAM) for your solution
• Current market size and growth rate
• Your target customer segment and their size
• Pricing model and ACV
• Customer acquisition strategy and CAC
• Gross margin and payback period
• Path to profitability

General Catalyst will ask all of these questions. If you don't have answers, they'll pass.

Show Traction

Traction in healthcare means:

• Pilot customers (even unpaid pilots count)
• Early revenue ($50K-500K ARR is ideal for Series A)
• Clinical or operational validation (did the product actually improve outcomes or reduce costs?)
• Team credibility (have you or your co-founders done this before?)

Build a Defensible Moat

What makes your company hard to copy? Possible answers:

• Proprietary data (clinical outcomes data, for example)
• Regulatory clearances (FDA, CMS coverage)
• Network effects (your platform gets better as more hospitals join)
• Switching costs (customers can't easily leave)

General Catalyst backs companies with clear moats. If your competitive advantage is just "we're better," that's not enough.

Partner with the Right Investors

Not all VCs are created equal for healthcare. You want investors who:

• Have healthcare domain expertise
• Have relationships with your target customers
• Can help with regulatory strategy
• Have portfolio companies that can be partners or acquirers
• Have patient capital (willing to wait 7-10 years for exit)

General Catalyst checks all these boxes. Other investors might not.

The Future: Where Healthcare Venture Is Heading

General Catalyst's $750 million healthcare bet signals where the market is going. The next generation of healthcare venture returns will come from:

1. AI-enabled care delivery. Companies that use AI to improve clinical decision-making, reduce administrative burden, or personalize treatment.

2. Home-based care. Aging population + rising hospital costs + patient preference = massive market for home-based diagnostics, monitoring, and treatment.

3. Precision medicine. Genomic data + AI + real-world evidence = ability to match patients to treatments at a molecular level.

4. Healthcare operations. Hospitals are desperate to reduce costs and improve efficiency. AI-powered operations platforms are a multi-billion-dollar opportunity.

5. Payer innovation. Health insurance is ripe for disruption. New models (direct primary care, employer self-insurance, etc.) are creating opportunities for tech-enabled solutions.

General Catalyst is investing across all five of these themes. If you're a founder in any of these areas, understanding their thesis gives you a roadmap for what to build and how to position yourself.

Why This Matters for Your Fundraising

Whether you're raising pre-seed, seed, or Series A, understanding how top-tier investors like General Catalyst think about healthcare gives you a competitive advantage. You can:

• Position your company correctly. Know what problem you're solving, who the buyer is, and what value you're creating.
• Build toward the metrics that matter. Focus on unit economics, traction, and defensible moats rather than vanity metrics.
• Tell a compelling story. Investors want to back founders who understand their market deeply and have a credible plan to win.
• Raise more capital at better terms. When you understand what investors are looking for, you can pitch more effectively and negotiate better valuations.

For more insights on capital raising strategy, check out 11 capital raising playbooks for startup founders and 10 fundraising myths founders still believe. These resources break down proven tactics from founders who have raised successfully.

The Bottom Line

General Catalyst's healthcare bets outperformed because they did three things right: they invested in a contrarian thesis when everyone else was looking elsewhere, they built deep operational expertise to support portfolio companies, and they had the patience to wait for real value creation rather than chasing quick exits.

The lesson for founders: the best venture returns don't come from hype. They come from solving real problems for customers who will pay premium prices, building companies with defensible moats, and executing with discipline over a long time horizon.

If you're building in healthcare, that's your playbook. If you're an investor, Capitaly's platform is where founders, operators, and investors discuss these exact topics daily. The insights, deal flow, and relationships you build there can accelerate your success-whether you're fundraising or investing.

The healthcare venture landscape is shifting. General Catalyst's $750 million bet is a signal that the best returns are still ahead. The question is: will you be positioned to capture them?

Key Takeaways for Founders and Investors

To recap the core insights:

For Founders:

• Healthcare is undervalued relative to its TAM and margin potential
• Unit economics matter more than growth rate
• Regulatory clearances and customer relationships are defensible moats
• Operational support from your investors is worth millions in future value
• Get early validation (pilots, revenue, clinical proof) before Series A

For Investors:

• Healthcare venture is less crowded than AI or climate tech
• Better unit economics and lower churn mean more predictable returns
• Hands-on operational support creates alpha
• Patient capital (7-10 year hold periods) unlocks more value
• Distribution relationships and domain expertise are competitive advantages

For Everyone:

• Contrarian investing works when you have deep expertise
• The best returns come from solving real problems, not chasing hype
• Building defensible businesses takes longer but pays off bigger
• Relationships and trust matter more in complex markets like healthcare

General Catalyst's healthcare playbook is a masterclass in thesis-driven venture investing. Whether you're a founder raising your first dollar or an investor deploying a billion-dollar fund, these lessons apply. The market rewards those who think differently, execute consistently, and have the patience to build real value.

For more on how top VCs build their theses and operate their portfolios, explore Capitaly's resources on venture strategy, founder profiles, and market analysis. The insights there will help you navigate your own capital raising journey or investment strategy with more confidence and clarity.